trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate
CAS: 125572-95-4
Ref. 3D-FD15679
1kg | 1.033,00 € | ||
50g | 156,00 € | ||
100g | 217,00 € | ||
250g | 406,00 € | ||
500g | 588,00 € |
Información del producto
- CDTA monohydrate1,2-Cyclohexylenedinitrilotetraacetic acid monohydrate
- 2,2',2'',2'''-[(1R,2R)-cyclohexane-1,2-diyldiammonio]tetraacetate monohydrate
- 2,2',2'',2'''-[(1R,2R)-cyclohexane-1,2-diyldinitrilo]tetraacetic acid hydrate
- 2,2',2'',2'''-[(1S,2S)-Cyclohexane-1,2-diyldinitrilo]tetraacetic acid monohydrate
- Glycine, N,N′-(1R,2R)-1,2-cyclohexanediylbis[N-(carboxymethyl)-, hydrate (1:1), rel-
- Glycine, N,N′-(1R,2R)-1,2-cyclohexanediylbis[N-(carboxymethyl)-, monohydrate, rel-
- Glycine, N,N′-1,2-cyclohexanediylbis[N-(carboxymethyl)-, monohydrate, trans-(±)-
- rel-N,N′-(1R,2R)-1,2-Cyclohexanediylbis[N-(carboxymethyl)glycine hydrate (1:1)
- trans-1,2-Diaminocyclohexane-N,N,N′,N′-tetraacetic acid monohydrate
Trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate (CDTA) is a chelating agent that has been shown to be effective in the treatment of some cancers. CDTA has been shown to inhibit the growth of tumor cells by binding to lysine residues on histones and DNA and inhibiting their acetylation. CDTA also prevents the genotoxicity induced by irradiation. CDTA can be used as an adjuvant in cancer therapy due to its ability to inhibit histone deacetylase activity. Trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate is synthesized from two amino acids: lysine and glutamic acid. This molecule is a polymeric compound composed of cyclic molecules linked together through amide bonds. These polymers are linear chains of
Propiedades químicas
Consulta técnica sobre: 3D-FD15679 trans-1,2-Diaminocyclohexane-N,N,N',N'-tetraacetic acid monohydrate
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.